デフォルト表紙
市場調査レポート
商品コード
1546612

破傷風トキソイドワクチンの世界市場レポート 2024年

Tetanus Toxoid Vaccine Global Market Report 2024


出版日
ページ情報
英文 175 Pages
納期
2~10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.26円
破傷風トキソイドワクチンの世界市場レポート 2024年
出版日: 2024年09月02日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2~10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

破傷風トキソイドワクチンの市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR7.3%で67億4,000万米ドルに成長します。予測期間中に予想される成長は、流通網拡大とともに研究開発へ投資が活発化していることに起因しています。この期間に予想される主な動向には、ワクチン技術進歩、新市場出現、革新的な製品やサービスイントロダクション、ワクチン需要高まりなどがあります。

破傷風トキソイドワクチン市場は、早産率の増加により成長が見込まれています。早産は妊娠37週未満に発生し、発育が不完全なために健康上の課題が生じる。この問題の要因としては、母親の高年齢化、ライフスタイルの選択、生殖補助医療などの医療介入、母親の健康状態、環境要因などが挙げられます。早産率の上昇は、破傷風やその他の予防可能な病気に対する予防接種を必要とする新生児や乳児の増加に伴い、破傷風トキソイドワクチンの需要を促進します。例えば、Office for National Statistics(国家統計局)は、英国における早産児の割合が2020年の7.4%から2021年には7.5%にわずかに増加すると報告しており、破傷風トキソイドワクチン市場の成長を促進する動向を浮き彫りにしています。

破傷風トキソイドワクチン市場の主要企業は、包括的な予防接種ソリューションに対する需要の高まりに対応するため、wP-IPVベースの5価ワクチンなどの先進ワクチンの開発に注力しています。wP-IPVベースの5価ワクチンは、複数の疾病予防を1回の注射で可能にするもので、不活化細菌やウイルスを使用し、疾病を引き起こすことなく免疫を刺激します。例えば、Panacea Biotec Limitedは2023年12月に、ジフテリア、破傷風、百日咳、ポリオ、B型インフルエンザを予防する完全液状の5価ワクチンEasyFourPolを発売しました。このワクチンは、現場での調製が不要なため投与が簡素化され、効率的かつ効果的な予防接種を実現します。

2021年3月、ステイブルファーマ社はBB-NCIPD社と提携し、ステイブルファーマ社が特許を有するStablevaX製剤と装置技術を用いて、熱的に安定な冷蔵庫不要の破傷風ジフテリア(Td)ワクチンを開発しました。この提携は、特に冷蔵インフラが限られている地域において、ワクチンの入手しやすさと安定性を高めることを目的としています。ブルガリアに拠点を置くBB-NCIPD社は、破傷風トキソイドワクチンを含むワクチン製造を専門としています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の市場規模と成長

  • 世界の破傷風トキソイドワクチン市場:促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の破傷風トキソイドワクチン市場の実績:規模と成長, 2018-2023
  • 世界の破傷風トキソイドワクチン市場の予測:規模と成長, 2023-2028, 2033F

第6章 市場セグメンテーション

  • 世界の破傷風トキソイドワクチン市場:ワクチンタイプ別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 破傷風トキソイド(TT)
  • ジフテリアと破傷風(DT)
  • 破傷風とジフテリア(Td)
  • ジフテリア、破傷風、百日咳(Dtap)
  • 破傷風、ジフテリア、百日咳(Tdap)
  • 五価
  • 六価
  • その他のタイプ
  • 世界の破傷風トキソイドワクチン市場:年齢層別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 小児
  • 成人
  • 世界の破傷風トキソイドワクチン市場:エンドユーザー別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 病院と診療所
  • 政府機関
  • その他のエンドユーザー

第7章 地域別・国別分析

  • 世界の破傷風トキソイドワクチン市場:地域別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 世界の破傷風トキソイドワクチン市場:国別、実績と予測, 2018-2023, 2023-2028F, 2033F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 破傷風トキソイドワクチン市場:競合情勢
  • 破傷風トキソイドワクチン市場:企業プロファイル
    • Sanofi S.A.
    • Novartis AG
    • LG Chem Ltd.
    • GlaxoSmithKline plc
    • Takeda Pharmaceutical Company Limited

第31章 その他の大手企業と革新的企業

  • Merck KGaA
  • Astellas Pharma Inc.
  • CSL Limited
  • Zoetis Inc.
  • Meiji Holdings Company Ltd.
  • Walvax Biotechnology
  • Shenzhen Kangtai Biological Products Co. Ltd.
  • AJ Vaccines AS
  • PT Bio Farma
  • Serum Institute of India Pvt. Ltd.
  • Bharat Biotech International Limited
  • Panacea Biotec Ltd.
  • Amson Vaccines and Pharma Pvt Ltd.
  • Incepta Vaccine Ltd.
  • Mitsubishi Tanabe Pharma Corporation

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと潜在的な分析

第36章 付録

目次
Product Code: r19498

The tetanus toxoid vaccine is designed to prevent tetanus, a severe bacterial infection caused by Clostridium tetani. It contains a form of the tetanus toxin, known as toxoid, which is harmless but prompts the immune system to generate antibodies against the toxin. These antibodies work by neutralizing the toxin produced by the bacteria, thereby providing protection against future infections.

The various types of tetanus toxoid vaccines are available. These include tetanus toxoid (Tt), diphtheria and tetanus (Dt), tetanus and diphtheria (Td), diphtheria, tetanus, and pertussis (Dtap), tetanus, diphtheria, and pertussis (Tdap), pentavalent, hexavalent, and others. Tetanus toxoid (Tt) vaccines consist of purified tetanus toxoid that stimulates the immune system to defend against tetanus-causing bacteria. These vaccines are used across different age groups, from pediatric to adult, in hospitals, clinics, government organizations, and other healthcare settings.

The tetanus toxoid vaccine market research report is one of a series of new reports from The Business Research Company that provides tetanus toxoid vaccine market statistics, including the tetanus toxoid vaccine industry global market size, regional shares, competitors with tetanus toxoid vaccine market share, detailed tetanus toxoid vaccine market segments, market trends, and opportunities, and any further data you may need to thrive in the tetanus toxoid vaccine industry. These tetanus toxoid vaccine market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tetanus toxoid vaccine market size has grown strongly in recent years. It will grow from $4.74 billion in 2023 to $5.08 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth observed in the historic period can be attributed to several factors, including heightened awareness, a rise in tetanus cases, and government initiatives aimed at immunization programs.

The tetanus toxoid vaccine market size is expected to see strong growth in the next few years. It will grow to $6.74 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The anticipated growth in the forecast period can be attributed to heightened investments in research and development, along with the expansion of distribution networks. Key trends expected during this period include advancements in vaccine technology, the emergence of new markets, the introduction of innovative products and services, and a rising demand for vaccines.

The tetanus toxoid vaccine market is expected to grow due to increasing rates of preterm births. Preterm birth, occurring before 37 weeks of gestation, presents health challenges due to incomplete development. Factors contributing to this issue include advanced maternal age, lifestyle choices, medical interventions such as assisted reproductive technologies, maternal health conditions, and environmental factors. The rise in preterm birth rates drives demand for tetanus toxoid vaccines as more newborns and infants require immunization against tetanus and other preventable diseases. For example, the Office for National Statistics reported a slight increase in the percentage of preterm live births from 7.4% in 2020 to 7.5% in 2021 in the UK, highlighting the trend driving the tetanus toxoid vaccine market growth.

Leading companies in the tetanus toxoid vaccine market are focusing on developing advanced vaccines, such as the wP-IPV-based pentavalent vaccine, to meet increasing demand for comprehensive immunization solutions. The wP-IPV-based pentavalent vaccine combines multiple disease protections into a single injection, using inactivated bacteria and viruses to stimulate immunity without causing illness. For instance, Panacea Biotec Limited launched EasyFourPol in December 2023, a fully-liquid pentavalent vaccine that protects against Diphtheria, Tetanus, Pertussis, Polio, and Haemophilus Influenza Type B infections. This vaccine simplifies administration by eliminating the need for on-site preparation, ensuring efficient and effective immunization.

In March 2021, Stablepharma Ltd. partnered with BB-NCIPD Ltd. to develop a thermally stable, fridge-free version of the tetanus-diphtheria (Td) vaccine using Stablepharma's patented StablevaX formulation and device technology. This collaboration aims to enhance vaccine accessibility and stability, particularly in regions with limited refrigeration infrastructure. BB-NCIPD Ltd., based in Bulgaria, specializes in vaccine production, including the Tetanus Toxoid vaccine.

Major companies operating in the tetanus toxoid vaccine market are Sanofi S.A., Novartis AG, LG Chem Ltd., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Astellas Pharma Inc., CSL Limited, Zoetis Inc., Meiji Holdings Company Ltd., Walvax Biotechnology, Shenzhen Kangtai Biological Products Co. Ltd., AJ Vaccines AS, PT Bio Farma, Serum Institute of India Pvt. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Amson Vaccines and Pharma Pvt Ltd., Incepta Vaccine Ltd., Mitsubishi Tanabe Pharma Corporation, BioNet-Asia Co. Ltd., Avalon Pharma Pvt. Ltd., Actiza Pharmaceutical Pvt. Ltd

North America was the largest region in the tetanus toxoid vaccine market in 2023. The regions covered in the tetanus toxoid vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the tetanus toxoid vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tetanus toxoid vaccine market consists of sales of live, attenuated, inactivated, subunit, conjugate, and toxoid vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tetanus Toxoid Vaccine Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tetanus toxoid vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tetanus toxoid vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tetanus toxoid vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Vaccine Type: Tetanus Toxoid (TT); Diphtheria And Tetanus (DT); Tetanus And Diphtheria (Td); Diphtheria, Tetanus, And Pertussis (Dtap); Tetanus, Diphtheria, And Pertussis (Tdap); Pentavalent; Hexavalent; Other Types
  • 2) By Age Group: Pediatric; Adult
  • 3) By End-User: Hospitals And Clinics; Government Organizations; Other End-Users
  • Companies Mentioned: Sanofi S.A.; Novartis AG; LG Chem Ltd.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tetanus Toxoid Vaccine Market Characteristics

3. Tetanus Toxoid Vaccine Market Trends And Strategies

4. Tetanus Toxoid Vaccine Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Tetanus Toxoid Vaccine Market Size and Growth

  • 5.1. Global Tetanus Toxoid Vaccine Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Tetanus Toxoid Vaccine Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Tetanus Toxoid Vaccine Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Tetanus Toxoid Vaccine Market Segmentation

  • 6.1. Global Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Tetanus Toxoid (TT)
  • Diphtheria And Tetanus (DT)
  • Tetanus And Diphtheria (Td)
  • Diphtheria, Tetanus, And Pertussis (Dtap)
  • Tetanus, Diphtheria, And Pertussis (Tdap)
  • Pentavalent
  • Hexavalent
  • Other Types
  • 6.2. Global Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pediatric
  • Adult
  • 6.3. Global Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals And Clinics
  • Government Organizations
  • Other End-Users

7. Tetanus Toxoid Vaccine Market Regional And Country Analysis

  • 7.1. Global Tetanus Toxoid Vaccine Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Tetanus Toxoid Vaccine Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Tetanus Toxoid Vaccine Market

  • 8.1. Asia-Pacific Tetanus Toxoid Vaccine Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Tetanus Toxoid Vaccine Market

  • 9.1. China Tetanus Toxoid Vaccine Market Overview
  • 9.2. China Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Tetanus Toxoid Vaccine Market

  • 10.1. India Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Tetanus Toxoid Vaccine Market

  • 11.1. Japan Tetanus Toxoid Vaccine Market Overview
  • 11.2. Japan Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Tetanus Toxoid Vaccine Market

  • 12.1. Australia Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Tetanus Toxoid Vaccine Market

  • 13.1. Indonesia Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Tetanus Toxoid Vaccine Market

  • 14.1. South Korea Tetanus Toxoid Vaccine Market Overview
  • 14.2. South Korea Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Tetanus Toxoid Vaccine Market

  • 15.1. Western Europe Tetanus Toxoid Vaccine Market Overview
  • 15.2. Western Europe Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Tetanus Toxoid Vaccine Market

  • 16.1. UK Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Tetanus Toxoid Vaccine Market

  • 17.1. Germany Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Tetanus Toxoid Vaccine Market

  • 18.1. France Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Tetanus Toxoid Vaccine Market

  • 19.1. Italy Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Tetanus Toxoid Vaccine Market

  • 20.1. Spain Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Tetanus Toxoid Vaccine Market

  • 21.1. Eastern Europe Tetanus Toxoid Vaccine Market Overview
  • 21.2. Eastern Europe Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Tetanus Toxoid Vaccine Market

  • 22.1. Russia Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Tetanus Toxoid Vaccine Market

  • 23.1. North America Tetanus Toxoid Vaccine Market Overview
  • 23.2. North America Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Tetanus Toxoid Vaccine Market

  • 24.1. USA Tetanus Toxoid Vaccine Market Overview
  • 24.2. USA Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Tetanus Toxoid Vaccine Market

  • 25.1. Canada Tetanus Toxoid Vaccine Market Overview
  • 25.2. Canada Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Tetanus Toxoid Vaccine Market

  • 26.1. South America Tetanus Toxoid Vaccine Market Overview
  • 26.2. South America Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Tetanus Toxoid Vaccine Market

  • 27.1. Brazil Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Tetanus Toxoid Vaccine Market

  • 28.1. Middle East Tetanus Toxoid Vaccine Market Overview
  • 28.2. Middle East Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Tetanus Toxoid Vaccine Market

  • 29.1. Africa Tetanus Toxoid Vaccine Market Overview
  • 29.2. Africa Tetanus Toxoid Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Tetanus Toxoid Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Tetanus Toxoid Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Tetanus Toxoid Vaccine Market Competitive Landscape And Company Profiles

  • 30.1. Tetanus Toxoid Vaccine Market Competitive Landscape
  • 30.2. Tetanus Toxoid Vaccine Market Company Profiles
    • 30.2.1. Sanofi S.A.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Novartis AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. LG Chem Ltd.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. GlaxoSmithKline plc
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Takeda Pharmaceutical Company Limited
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Tetanus Toxoid Vaccine Market Other Major And Innovative Companies

  • 31.1. Merck KGaA
  • 31.2. Astellas Pharma Inc.
  • 31.3. CSL Limited
  • 31.4. Zoetis Inc.
  • 31.5. Meiji Holdings Company Ltd.
  • 31.6. Walvax Biotechnology
  • 31.7. Shenzhen Kangtai Biological Products Co. Ltd.
  • 31.8. AJ Vaccines AS
  • 31.9. PT Bio Farma
  • 31.10. Serum Institute of India Pvt. Ltd.
  • 31.11. Bharat Biotech International Limited
  • 31.12. Panacea Biotec Ltd.
  • 31.13. Amson Vaccines and Pharma Pvt Ltd.
  • 31.14. Incepta Vaccine Ltd.
  • 31.15. Mitsubishi Tanabe Pharma Corporation

32. Global Tetanus Toxoid Vaccine Market Competitive Benchmarking

33. Global Tetanus Toxoid Vaccine Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Tetanus Toxoid Vaccine Market

35. Tetanus Toxoid Vaccine Market Future Outlook and Potential Analysis

  • 35.1 Tetanus Toxoid Vaccine Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Tetanus Toxoid Vaccine Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Tetanus Toxoid Vaccine Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer